Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › Continuous glucose monitoring as equinox of nocturnal and daytime hypoglycaemia in type 1 diabetes : insights from the randomized controlled HypoDE trial

Publication

Continuous glucose monitoring as equinox of nocturnal and daytime hypoglycaemia in type 1 diabetes : insights from the randomized controlled HypoDE trial

Hermanns, Norbert; Heinemann, Lutz; Kulzer, Bernhard; u. a. (2025): Continuous glucose monitoring as equinox of nocturnal and daytime hypoglycaemia in type 1 diabetes : insights from the randomized controlled HypoDE trial, in: Diabetes research and clinical practice, Amsterdam: Elsevier, Jg. 224, Nr. 112228, S. 1–8, doi: 10.1016/j.diabres.2025.112228.

Details

Faculty/Chair
Faculty/Professorship
Author
Heinemann, Lutz
Schäfer, Arne
Jacobsen, Malte
Title of the Journal
Diabetes research and clinical practice
ISSN
1872-8227
0168-8227
Publisher Information
Elsevier : Amsterdam
Year of publication
2025
Volume
224
Issue
112228
Language
English
DOI
Abstract

Aims:

This study re-analysed data from the HypoDE trial to assess the prevalence of nocturnal hypoglycaemia, evaluate the impact of continuous glucose monitoring (CGM) on nocturnal and daytime hypoglycaemia, and explore their influence on severe hypoglycaemia (SH).

Methods:

The HypoDE trial was a randomized controlled trial involving 141 adults with type 1 diabetes, impaired hypoglycaemia awareness, or prior SH. Participants were randomized to CGM (Dexcom G5) or self-monitoring of blood glucose (control). Outcomes included the percentage of time spent in hypoglycaemia (<3.9 mmol/L, <3.0 mmol/L), episode duration, and SH incidence.

Results:

At baseline, nocturnal hypoglycaemia (<3.0 mmol/L) exposure exceeded daytime by 1.4 percentage points (95 % CI 0.6–2.2; p < 0.002), with episodes lasting 30.7 min longer (CI 21.5–39.9). Using CGM, these differences disappeared (<3.0 mmol/L: 0.3 percentage points, CI 0.7–1.3), while they persisted in the control group. Daytime hypoglycaemia significantly increased SH risk (IRR 1.10 per percentage point, CI 1.01–1.21; IRR 1.04 per minute, CI 1.01–1.07).

Conclusions:

CGM effectively reduced nocturnal and daytime hypoglycaemia. Without CGM, nocturnal hypoglycaemia contributes to daytime risks, while daytime hypoglycaemia elevates SH risk. Expanding CGM access and addressing nocturnal hypoglycaemia in resource-limited settings are critical.

Trial registrationClinicaltrials.gov: NCT02671968.

Keywords
Diabetestechnology
Continuous glucose monitoring
Nocturnal hypoglycaemia
Severe hypoglycemia
DDC Classification
150 Psychology
RVK Classification
CU 1000
Type
Article
URI
Activation date
2025-05-23
Project(s)

Permalink: https://fis.uni-bamberg.de/handle/uniba/108385 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.